Back to Search
Start Over
Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis.
- Source :
-
Medicine [Medicine (Baltimore)] 2019 Nov; Vol. 98 (44), pp. e17813. - Publication Year :
- 2019
-
Abstract
- Background: To evaluate the short-term efficacy, long-term efficacy, and adverse events (AEs) of elemene plus transcatheter arterial chemoembolization (TACE) in comparison with TACE alone for the treatment of hepatocellular carcinoma (HCC).<br />Methods: PubMed, EMBASE, the Cochrane Library, the Chinese Scientific Journal Full-text Database, Wanfang Data, CBM, and VIP were searched by 2 reviewers using the same search strategy for clinical studies on elemene plus TACE in the treatment of HCC. These articles were screened according to pre-established inclusion and exclusion criteria, and the qualities of the included studies were assessed using the Newcastle-Ottawa scale. The primary outcomes were the objective response rate (ORR), the 1-year survival rate and AEs. Review Manager 5.3 and Stata 15.0 were used for the meta-analysis.<br />Results: A total of 10 studies involving 543 patients (TACE + elemene = 277, TACE alone = 266) were included. The results showed that the ORR was significantly improved in the combined treatment group compared to the TACE alone group (odds ratio [OR] = 2.72, 95% confidence interval [CI]: 1.84-4.00, P < .05). TACE + elemene significantly increased the 1-year survival rate (OR = 2.79, 95% CI: 1.58-4.95, P < .05). We also found no significant difference in gastrointestinal reactions (OR = 0.97, 95% CI: 0.57-1.64, P = .90), fever (OR = 0.80, 95% CI: 0.37-1.71, P = .56), or bone marrow suppression (OR = 0.73, 95% CI: 0.44-1.22, P = .23) between the 2 groups.<br />Conclusion: Based on current findings, TACE + elemene injection may improve the ORR and the 1-year survival rate for HCC patients compared to TACE alone. Arterial perfusion may be superior to intravenous guttae.
- Subjects :
- Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Catheterization
Chemoembolization, Therapeutic adverse effects
Humans
Injections, Intra-Arterial
Sesquiterpenes administration & dosage
Sesquiterpenes adverse effects
Antineoplastic Agents therapeutic use
Carcinoma, Hepatocellular drug therapy
Chemoembolization, Therapeutic methods
Liver Neoplasms drug therapy
Sesquiterpenes therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1536-5964
- Volume :
- 98
- Issue :
- 44
- Database :
- MEDLINE
- Journal :
- Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 31689867
- Full Text :
- https://doi.org/10.1097/MD.0000000000017813